Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1081–1104 of 7,072 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Breast Neoplasm Clear all
Completed Phase 3 Interventional Results available

A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer

NCT01358877
View directory record Official record
Conditions
Breast Cancer
Interventions
5-Fluorouracil, Carboplatin, Cyclophosphamide, Docetaxel, Doxorubicin, Epirubicin, Paclitaxel, Pertuzumab, Placebo, Trastuzumab
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
4,804 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
114
States / cities
Scottsdale, Arizona • Everett, California • Greenbrae, California + 92 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Phase 1 Interventional

Study of Continuous OSI-906 Dosing

NCT00514007
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
OSI-906
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 25, 2026, 4:42 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Vitamin D and Physical Activity on Bone Health

NCT01419730
View directory record Official record
Conditions
Bone Metabolism Biomarkers, Bone Mineral Density, Physical Fitness
Interventions
Vitamin D3, Physical Activity
Drug · Behavioral
Lead sponsor
University of Rochester
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2026
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Aug 5, 2026 · Synced Oct 25, 2026, 4:42 PM EDT
Completed No phase listed Observational

Tamoxifen Pharmacogenetics and Clinical Effects

NCT00228930
View directory record Official record
Conditions
Breast Cancer
Interventions
Tamoxifen (pharmacodynamic analysis)
Drug
Lead sponsor
National Institute of General Medical Sciences (NIGMS)
NIH
Eligibility
18 Years to 70 Years · Female only
Enrollment
297 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
2
States / cities
Indianapolis, Indiana • Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 25, 2008 · Synced Oct 25, 2026, 4:42 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Multi-scale Modeling of Breast Conserving Therapy

NCT02310711
View directory record Official record
Conditions
Breast Cancer
Interventions
Standard of Care
Other
Lead sponsor
The Methodist Hospital Research Institute
Other
Eligibility
30 Years to 80 Years · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2020
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 10, 2018 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Phase 2 Interventional

Expanding Rural Access: Distance Delivery of Support

NCT00186511
View directory record Official record
Conditions
Breast Cancer, Stress Disorders, Post-Traumatic, Depression
Interventions
workbook/journal on coping with breast cancer, supportive expressive group therapy using videoconferencing
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
21 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2006 · Synced Oct 25, 2026, 4:42 PM EDT
Withdrawn No phase listed Observational Accepts healthy volunteers

A Pilot Study of Tumor-Derived Exosomes as Diagnostic and Prognostic Markers in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

NCT01344109
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Not listed
Lead sponsor
Leo W. Jenkins Cancer Center
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2014
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 25, 2026, 4:42 PM EDT
Active, not recruiting Not applicable Interventional

Robotic vs. Open NSM for Early Stage Breast Cancer

NCT05720039
View directory record Official record
Conditions
Breast Cancer Female, Breast Cancer, Breast Cancer, Early-Onset, Breast Disease, Breast
Interventions
Robotic NSM, Open NSM
Device · Procedure
Lead sponsor
Intuitive Surgical
Industry
Eligibility
21 Years and older · Female only
Enrollment
204 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
15
States / cities
Irvine, California • Los Angeles, California • Jacksonville, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2026 · Synced Oct 25, 2026, 4:42 PM EDT
Recruiting No phase listed Observational

Safe and Explainable AI

NCT06694181
View directory record Official record
Conditions
Artifical Inteligence, Cardiology, Breast Cancer, Sepsis
Interventions
AI-PERSONALIZED CLINICAL DECISION SUPPORT
Other
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
300,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Not applicable Interventional Results available

Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative Breast Cancer

NCT02158507
View directory record Official record
Conditions
Metastatic Triple Negative Breast Cancer
Interventions
Combination of Veliparib + Lapatinib
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jan 22, 2026 · Synced Oct 25, 2026, 4:42 PM EDT
Terminated Phase 4 Interventional

Using the Conture® Multi-Lumen Balloon to Deliver Accelerated Partial Breast Brachytherapy

NCT00699101
View directory record Official record
Conditions
Breast Cancer
Interventions
Conture Multi-Lumen Balloon
Device
Lead sponsor
SenoRx, Inc.
Industry
Eligibility
50 Years and older
Enrollment
342 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 17, 2013 · Synced Oct 25, 2026, 4:42 PM EDT
Not yet recruiting Phase 2 Interventional

EMBRACE (EMPA in BReast Cancer for Activity and Cardiac ProtEction)

NCT07883512
View directory record Official record
Conditions
Breast Cancer, Supportive Care in Cancer
Interventions
Empagliflozin
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Responsiveness to Acute Changes in Exercise and Relaxation (RACER) Trial

NCT03702712
View directory record Official record
Conditions
Breast Cancer
Interventions
Aerobic Exercise and Relaxation, Aerobic Exercise Only, Relaxation Only
Behavioral
Lead sponsor
University of Illinois at Urbana-Champaign
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Urbana, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 25, 2026, 4:42 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prospective Radiologic Evaluation of Changes Following Fat Grafting

NCT01343030
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 84 Years · Female only
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Not applicable Interventional Results available

Alcohol and Breast Cancer (ABC) Trial

NCT05423730
View directory record Official record
Conditions
ER+ Breast Cancer, Breast Cancer, Aromatase Inhibitors
Interventions
White Wine, Grape Juice
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
21 Years to 90 Years · Female only
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 20, 2024 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Phase 2 Interventional

Trial of Active Immunotherapy With Globo H-KLH (OPT-822) in Metastatic Breast Cancer Subjects

NCT01516307
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
OPT-822/OPT-821(30 μg/100 μg), Phosphate Buffer Saline (PBS), Cyclophosphamide
Biological · Drug
Lead sponsor
OBI Pharma, Inc
Industry
Eligibility
21 Years and older · Female only
Enrollment
349 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
13
States / cities
Birmingham, Alabama • Fullerton, California • La Jolla, California + 10 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 25, 2026, 4:42 PM EDT
Completed No phase listed Observational

Weight Loss Counseling for African American Women Who Are Breast Cancer Survivors

NCT00872677
View directory record Official record
Conditions
Breast Cancer, Obesity, Weight Changes
Interventions
Diet, Spiritual counseling
Behavioral · Other
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years to 70 Years · Female only
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Apr 29, 2013 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Phase 3 Interventional Results available

Novel Epothilone Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer

NCT00080301
View directory record Official record
Conditions
Breast Cancer, Metastases
Interventions
Ixabepilone + Capecitabine, Capecitabine
Drug
Lead sponsor
R-Pharm
Industry
Eligibility
18 Years and older · Female only
Enrollment
752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
32
States / cities
Little Rock, Arkansas • San Francisco, California • Vallejo, California + 29 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study to Evaluate Relacorilant (CORT125134) in Combination With Nab-paclitaxel in Participants With Solid Tumors

NCT02762981
View directory record Official record
Conditions
Solid Tumors
Interventions
Relacorilant with nab-paclitaxel
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
4
States / cities
Scottsdale, Arizona • San Francisco, California • Chicago, Illinois + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2022 · Synced Oct 25, 2026, 4:42 PM EDT
Recruiting Not applicable Interventional

Generative AI Patient Education Module for Breast Oncology

NCT07512271
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer, Carcinoma of the Breast
Interventions
Survey (Participant), OpenEvidence CareConnect, Survey (Provider)
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Breast Cancer Chemoprevention by SOM230, an IGF-I Action Inhibitor: A Proof of Principle Trial

NCT01372644
View directory record Official record
Conditions
Atypical Ductal Breast Hyperplasia, Lobular Carcinoma in Situ (LCIS), Atypical Lobular Hyperplasia (ALH) of Breast
Interventions
SOM 230 / Pasireotide
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
21 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 5, 2016 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Phase 2 Interventional

Docetaxel in Treating Patients With Solid Tumors

NCT00003565
View directory record Official record
Conditions
Bladder Cancer, Breast Cancer, Head and Neck Cancer, Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
docetaxel
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
109 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2008
U.S. locations
72
States / cities
Anniston, Alabama • La Jolla, California • San Diego, California + 52 more
Source: ClinicalTrials.gov public record
Updated Jul 14, 2016 · Synced Oct 25, 2026, 4:42 PM EDT
Completed Early Phase 1 Interventional

18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases

NCT04752267
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8, Glioma, Malignant Brain Neoplasm, Metastatic Breast Carcinoma, Metastatic Colon Carcinoma, Metastatic Kidney Carcinoma, Metastatic Lung Carcinoma, Metastatic Malignant Neoplasm in the Brain, Metastatic Melanoma, Pathologic Stage IV Cutaneous Melanoma AJCC v8, Prognostic Stage IV Breast Cancer AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Stage IVA Colon Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Colon Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IVC Colon Cancer AJCC v8
Interventions
Computed Tomography, 18F-FMAU, Multiparametric Magnetic Resonance Imaging, Positron Emission Tomography
Procedure · Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 24, 2024 · Synced Oct 25, 2026, 4:42 PM EDT
Completed No phase listed Observational

A Cost-Effective Handheld Breast Scanner for Use in Low Resource Environments: A Validation Study

NCT02814292
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 27, 2016 · Synced Oct 25, 2026, 4:42 PM EDT